What type of study is this?

This is a Animal Study study (also classified as: Validation Study).

December 8, 2025BloodOpen Access

In Vivo RNA delivery by targeted lipid nanoparticles enable gene editing in hematopoietic stem cells and T cells

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis demonstrates efficient gene editing in hematopoietic stem cells, suggesting promising gene therapy for sickle cell disease.

Gene editing achieved approximately 75% beta-2 microglobulin editing in hematopoietic stem cells.
Lipid nanoparticles enhanced delivery efficiency in bone marrow while minimizing liver expression by 11-fold.
Targeted approach using our Gene Writing platform optimized RNA delivery to hematopoietic stem cells.
Significant implications for treating sickle cell disease and improving gene therapy techniques for various conditions.

Palchaudhuri et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis demonstrates efficient gene editing in hematopoietic stem cells, suggesting promising gene therapy for sickle cell disease.